Title,Authors,Platform,Cited_url,Cited_count,Year
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update,"DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...","PloS one 4 (3), e4724",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14545780826523943818,870,2009
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation,TIHIVC Study,"Science (New York, NY) 330 (6010), 1551","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4554467849365634593,8313021439337597239",770,2010
Human immunodeficiency virus reverse transcriptase and protease sequence database,"SY Rhee, MJ Gonzales, R Kantor, BJ Betts, J Ravela, RW Shafer","Nucleic acids research 31 (1), 298-303",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9951577681258209086,743,2003
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection,"PM Small, RW Shafer, PC Hopewell, SP Singh, MJ Murphy, E Desmond, ...","New England Journal of Medicine 328 (16), 1137-1144",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7706229892779600982,702,1993
2011 update of the drug resistance mutations in HIV-1,"VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ...","Topics in antiviral medicine 19 (4), 156","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12578518607051180170,12123088571161982284",639,2011
2017 update of the drug resistance mutations in HIV-1,"AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...","Topics in antiviral medicine 24 (4), 132","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17448385168379805136,5609003506529813858,976844745339368446,9957960635268255609",567,2016
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.,"RW Shafer, LM Smeaton, GK Robbins, SW De Gruttola, Victor, Snyder, ...","New England Journal of Medicine 349 (24), 2304-15","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6856562840166374033,3621908158921400615",558,2003
Web resources for HIV type 1 genotypic-resistance test interpretation,"TF Liu, RW Shafer","Clinical infectious diseases 42 (11), 1608-1618",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=42885337160986648,469,2006
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance,"C Wang, Y Mitsuya, B Gharizadeh, M Ronaghi, RW Shafer","Genome research 17 (8), 1195-1201",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7228202645354559741,465,2007
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART,"RW Shafer, JM Schapiro","AIDS reviews 10 (2), 67",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15904759732312467566,397,2008
Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection.,"RW Shafer, DS Kim, JP Weiss, JM Quale","Medicine 70 (6), 384-397",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11691230623197153177,388,1991
Genotypic testing for human immunodeficiency virus type 1 drug resistance,RW Shafer,"Clinical microbiology reviews 15 (2), 247-277",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10245401423162688139,378,2002
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance,"RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ...","AIDS (London, England) 21 (2), 215",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3567845050160283737,363,2007
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration,"R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...","PLoS medicine 2 (4), e112",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14717039624283314003,362,2005
HIV-1 antiretroviral resistance,"MW Tang, RW Shafer","Drugs 72 (9), e1-e25",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16057286157295013324,308,2012
Update of the drug resistance mutations in HIV-1: March 2013,"VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ...","Topics in antiviral medicine 21 (1), 6",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9579267076627265154,295,2013
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.,"AK Iversen, RW Shafer, K Wehrly, MA Winters, JI Mullins, B Chesebro, ...","Journal of Virology 70 (2), 1086-1090",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8758996256445206267,295,1996
Rationale and uses of a public HIV drug‐resistance database,RW Shafer,"The Journal of infectious diseases 194 (Supplement_1), S51-S58",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=407874021006190177,287,2006
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study,"DW Haas, LM Smeaton, RW Shafer, GK Robbins, GD Morse, L Labbé, ...","The Journal of infectious diseases 192 (11), 1931-1942",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2212812294476681146,282,2005
Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade,"RW Shafer, BR Edlin","Clinical infectious diseases 22 (4), 683-704",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3455856621234813427,264,1996
Genotypic predictors of human immunodeficiency virus type 1 drug resistance,"SY Rhee, J Taylor, G Wadhera, A Ben-Hur, DL Brutlag, RW Shafer","Proceedings of the National Academy of Sciences 103 (46), 17355-17360",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16384617859386469941,251,2006
HIV-1 genotypic resistance patterns predict response to saquinavir–ritonavir therapy in patients in whom previous protease inhibitor therapy had failed,"AR Zolopa, RW Shafer, A Warford, JG Montoya, P Hsu, D Katzenstein, ...","Annals of internal medicine 131 (11), 813",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7491920789887220809,251,1999
Viral population estimation using pyrosequencing,"N Eriksson, L Pachter, Y Mitsuya, SY Rhee, C Wang, B Gharizadeh, ...","PLoS computational biology 4 (5), e1000074",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3325740226380178202,250,2008
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments,"TD Wu, CA Schiffer, MJ Gonzales, J Taylor, R Kantor, S Chou, D Israelski, ...","Journal of virology 77 (8), 4836-4847",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13376769511139015201,249,2003
Blastomycosis in patients with the acquired immunodeficiency syndrome,"PG Pappas, JC Pottage, WG Powderly, VJ Fraser, CW Stratton, ...","Annals of internal medicine 116 (10), 847-853",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14629514757833125470,236,1992
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384,"GK Robbins, JG Spritzler, ES Chan, DM Asmuth, RT Gandhi, ...","Clinical Infectious Diseases 48 (3), 350-361",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4457139816519983492,235,2009
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.,"MA Winters, KL Coolley, YA Girard, DJ Levee, H Hamdan, RW Shafer, ...","The Journal of clinical investigation 102 (10), 1769-1775",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5990948214719330439,232,1998
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)–treated patients and NRTI-naive patients,"S Margeridon-Thermet, NS Shulman, A Ahmed, R Shahriar, T Liu, ...","The Journal of infectious diseases 199 (9), 1275-1285",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6096443006108377530,226,2009
Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients,"RW Shafer, MA Winters, S Palmer, TC Merigan","Annals of internal medicine 128 (11), 906-911",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4717423236285965597,222,1998
Combination Therapy with Zidovudine and Didanosine Selects for Drug-Resistant Human Immunodeficiency Virus Type 1 Strains with Unique Patterns of ,"RW Shafer, MJ Kozal, MA Winters, AKN Iversen, DA Katzenstein, ...","Journal of Infectious Diseases 169 (4), 722-729",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17614426888565298311,222,1994
"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","MP Dube, RA Parker, P Tebas, SK Grinspoon, RA Zackin, GK Robbins, ...","Aids 19 (16), 1807-1818",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10172535941810921199,220,2005
HIV-1 integrase inhibitor resistance and its clinical implications,"JL Blanco, V Varghese, SY Rhee, JM Gatell, RW Shafer","Journal of Infectious Diseases 203 (9), 1204-1214",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16051735550738309495,216,2011
Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient-and sequence-level meta-analysis,"SY Rhee, JL Blanco, MR Jordan, J Taylor, P Lemey, V Varghese, ...","PLoS medicine 12 (4), e1001810",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5064858619685289920,190,2015
A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution,"RJ Gifford, A Katzourakis, M Tristem, OG Pybus, M Winters, RW Shafer","Proceedings of the National Academy of Sciences 105 (51), 20362-20367",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14798755849635954926,181,2008
A highly prevalent and genetically diversified Picornaviridae genus in South Asian children,"A Kapoor, J Victoria, P Simmonds, E Slikas, T Chieochansin, A Naeem, ...","Proceedings of the National Academy of Sciences 105 (51), 20482-20487",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11483669969791587986,177,2008
Effect of baseline-and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384,"RT Gandhi, J Spritzler, E Chan, DM Asmuth, B Rodriguez, TC Merigan, ...","JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (4), 426-434",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14132831421382557497,175,2006
HIV-1 protease mutations and protease inhibitor cross-resistance,"SY Rhee, J Taylor, WJ Fessel, D Kaufman, W Towner, P Troia, P Ruane, ...","Antimicrobial agents and chemotherapy 54 (10), 4253-4261",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14720586603496689152,170,2010
Drug resistance mutations in HIV-1,"RT D’Aquila, JM Schapiro, F Brun-Vézinet, B Clotet, B Conway, ...","Top HIV Med 11 (3), 92-96",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9292650874951599596,165,2003
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance,"RJ Gifford, TF Liu, SY Rhee, M Kiuchi, S Hue, D Pillay, RW Shafer","Bioinformatics 25 (9), 1197-1198",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15573199405858520849,162,2009
Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study,"T Hulgan, DW Haas, JL Haines, MD Ritchie, GK Robbins, RW Shafer, ...","Aids 19 (13), 1341-1349",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13489747975704634549,160,2005
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.,"MA Winters, RW Shafer, RA Jellinger, G Mamtora, T Gingeras, ...","Antimicrobial agents and chemotherapy 41 (4), 757-762",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14299572051080466089,155,1997
"Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro","KK Koelsch, L Liu, R Haubrich, S May, D Havlir, HF Günthard, CC Ignacio, ...","The Journal of infectious diseases 197 (3), 411-419",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17093369684318761950,150,2008
Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development,"S Palmer, RW Shafer, TC Merigan","AIDS (London, England) 13 (6), 661",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16714954950764362166,150,1999
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients,"MJ Kozal, RW Shafer, MA Winters, DA Katzenstein, TC Merigan","Journal of Infectious Diseases 167 (3), 526-532",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=706730289202892202,150,1993
Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy,"R Kantor, RW Shafer, S Follansbee, J Taylor, D Shilane, L Hurley, ...","AIDS (London, England) 18 (11), 1503",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9756803657663220450,146,2004
Human immunodeficiency virus reverse transcriptase and protease sequence database,"RW Shafer, D Stevenson, B Chan","Nucleic acids research 27 (1), 348-352",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3842925733308059510,146,1999
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors,"MJ Gonzales, TD Wu, J Taylor, I Belitskaya, R Kantor, D Israelski, S Chou, ...","AIDS (London, England) 17 (6), 791",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6444416302080592132,145,2003
Drug resistance mutations in HIV-1.,"RT d'Aquila, A International, JM Schapiro, F Brun-Vezinet, B Clotet, ...","Topics in HIV medicine: a publication of the International AIDS Society, USA …",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5872287500042103916,140,2002
HIV sequence databases,"C Kuiken, B Korber, RW Shafer","AIDS reviews 5 (1), 52",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15727484161629784978,135,2003
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.,TRS Group,Lancet Infectious Diseases,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13400561553701642482,134,2016
"HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS.","RW Shafer, KD Chirgwin, AE Glatt, MA Dahdouh, SH Landesman, ...","AIDS (London, England) 5 (4), 399-405",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3914611771009860695,131,1991
A highly divergent picornavirus in a marine mammal,"A Kapoor, J Victoria, P Simmonds, C Wang, RW Shafer, R Nims, ...","Journal of virology 82 (1), 311-320",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9005358683207621356,129,2008
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria,"CV Plowe, C Roper, JW Barnwell, CT Happi, HH Joshi, W Mbacham, ...","Malaria journal 6 (1), 121",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=755919433249777896,124,2007
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance,"SY Rhee, WJ Fessel, AR Zolopa, L Hurley, T Liu, J Taylor, DP Nguyen, ...","The Journal of infectious diseases 192 (3), 456-465",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5981240206743784516,123,2005
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine,"D Lecossier, NS Shulman, L Morand-Joubert, RW Shafer, V Joly, ...","JAIDS Journal of Acquired Immune Deficiency Syndromes 38 (1), 37-42",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16748076556846158259,123,2005
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms,"J Ravela, BJ Betts, F Brun-Vézinet, AM Vandamme, D Descamps, ...","Journal of acquired immune deficiency syndromes (1999) 33 (1), 8",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1760789675441915187,118,2003
Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation,"MJ Gonzales, E Delwart, SY Rhee, R Tsui, AR Zolopa, J Taylor, ...","The Journal of infectious diseases 188 (3), 397-405",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18422324939924021983,116,2003
"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","CK Woods, CJ Brumme, TF Liu, CKS Chui, AL Chu, B Wynhoven, TA Hall, ...","Journal of clinical microbiology 50 (6), 1936-1942",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9943859375047183979,113,2012
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors,"SY Rhee, TF Liu, M Kiuchi, R Zioni, RJ Gifford, SP Holmes, RW Shafer","Retrovirology 5 (1), 74",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10979022875233612496,111,2008
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation …,"V Varghese, R Shahriar, SY Rhee, T Liu, BB Simen, M Egholm, ...","Journal of acquired immune deficiency syndromes (1999) 52 (3), 309-315",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4039474349955600738,107,2009
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent,"J Snoeck, R Kantor, RW Shafer, K Van Laethem, K Deforche, ...","Antimicrobial agents and chemotherapy 50 (2), 694-701",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8594869791206480814,107,2006
Frequency of Mycobacterium tuberculosis bacteremia in patients with tuberculosis in an area endemic for AIDS,"RW Shafer, R Goldberg, M Sierra, AE Glatt","Am Rev Respir Dis 140 (6), 1611-1613",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13168423702272079216,107,1989
HIV-1 subtype B protease and reverse transcriptase amino acid covariation,"SY Rhee, TF Liu, SP Holmes, RW Shafer","PLoS computational biology 3 (5), e87",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3133304051787302746,105,2007
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine …,"LM Demeter, RW Shafer, PM Meehan, J Holden-Wiltse, MA Fischl, ...","Antimicrobial agents and chemotherapy 44 (3), 794-797",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12229945496989863771,105,2000
Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1,"RW Shafer, DA Vuitton","Biomedicine & pharmacotherapy 53 (2), 73-86",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7859494930269705563,105,1999
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz …,"N Shulman, AR Zolopa, D Passaro, RW Shafer, W Huang, D Katzenstein, ...","Aids 15 (9), 1125-1132",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14865093821892148116,104,2001
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection,"JJ Lok, RJ Bosch, CA Benson, AC Collier, GK Robbins, RW Shafer, ...","AIDS (London, England) 24 (12), 1867",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5002580621634534074,101,2010
Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs,"R Kantor, R Machekano, MJ Gonzales, K Dupnik, JM Schapiro, ...","Nucleic Acids Research 29 (1), 296-299",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4682167496487669467,100,2001
HIV-1 drug resistance and resistance testing,"DS Clutter, MR Jordan, S Bertagnolio, RW Shafer","Infection, Genetics and Evolution 46, 292-307",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3698541445111031779,99,2016
Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations,"Y Mitsuya, V Varghese, C Wang, TF Liu, SP Holmes, P Jayakumar, ...","Journal of virology 82 (21), 10747-10755",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5179642511899006857,98,2008
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in an immunocompetent patient,"RW Shafer, SP Singh, C Larkin, PM Small","Tubercle and Lung Disease 76 (6), 575-577",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13023277875373255283,98,1995
"Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic …","MJ Gonzales, RN Machekano, RW Shafer","The Journal of infectious diseases 184 (8), 998-1006",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9120796706087707711,96,2001
The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors,"RW Shafer, R Kantor, MJ Gonzales","AIDS reviews 2 (4), 211",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3531502307017097374,95,2000
"Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing","SY Rhee, T Liu, J Ravela, MJ Gonzales, RW Shafer","Antimicrobial agents and chemotherapy 48 (8), 3122-3126",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13146007613539752062,93,2004
", and Other Nontuberculous Mycobacteria in an Area of Endemicity for AIDS","RW Shafer, MF Sierra","Clinical infectious diseases 15 (1), 161-162",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7991648923077813407,93,1992
HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes,"SY Rhee, R Kantor, DA Katzenstein, R Camacho, L Morris, ...","AIDS (London, England) 20 (5), 643",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3010191665335764733,92,2006
Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries,"RW Shafer, DR Jung, BJ Betts","Nature medicine 6 (11), 1290",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7124703797939508496,92,2000
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy,"RW Shafer, AKN Iversen, MA Winters, E Aguiniga, DA Katzenstein, ...","Journal of Infectious Diseases 172 (1), 70-78",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7231734680065184965,92,1995
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy,"MJ Kozal, K Kroodsma, MA Winters, RW Shafer, B Efron, DA Katzenstein, ...","Annals of internal medicine 121 (4), 263-268",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7973167472154771707,91,1994
Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies,"RW Shafer, SY Rhee, DE Bennett","Antiviral therapy 13 (0 2), 59",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2629266630110867141,90,2008
A review of the virological efficacy of the 4 World Health Organization–recommended tenofovir-containing regimens for initial HIV therapy,"MW Tang, PJ Kanki, RW Shafer","Clinical Infectious Diseases 54 (6), 862-875",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12221330263254236744,85,2012
Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations,"JA Johnson, JF Li, X Wei, J Lipscomb, D Bennett, A Brant, M Cong, ...","PloS one 2 (7), e638",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17136727013580444000,84,2007
The HIVdb system for HIV-1 genotypic resistance interpretation,"MW Tang, TF Liu, RW Shafer","Intervirology 55 (2), 98-101",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14836082402491482352,83,2012
Clinically validated genotype analysis: guiding principles and statistical concerns.,"F Brun-Vezinet, D Costagliola, MA Khaled, V Calvez, F Clavel, B Clotet, ...","Antiviral therapy 9 (4), 465-478",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10395980308309511673,83,2004
Human immunodeficiency virus reverse transcriptase and protease sequence database,"RW Shafer, DR Jung, BJ Betts, Y Xi, MJ Gonzales","Nucleic Acids Research 28 (1), 346-348",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14078526877830799561,83,2000
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study,"AA Motsinger, MD Ritchie, RW Shafer, GK Robbins, GD Morse, L Labbe, ...","Pharmacogenetics and genomics 16 (11), 837-845",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=590138313893819976,78,2006
The mitochondrial pharmacogenomics of haplogroup T: MTND2* LHON4917G and antiretroviral therapy-associated peripheral neuropathy,"JA Canter, DW Haas, AR Kallianpur, MD Ritchie, GK Robbins, RW Shafer, ...","The pharmacogenomics journal 8 (1), 71-77",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5385387631428861000,76,2008
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients,"RW Shafer, K Hertogs, AR Zolopa, A Warford, S Bloor, BJ Betts, ...","Journal of clinical microbiology 39 (4), 1522-1529",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7458420036352965118,76,2001
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors,"RW Shafer, P Hsu, AK Patick, C Craig, V Brendel","Journal of virology 73 (7), 6197-6202",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7277701176343336034,76,1999
A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies,"RW Shafer, K Dupnik, MA Winters, SH Eshleman","HIV sequence compendium 2001, 1",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=855320452675257380,71,2001
Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment,"RW Shafer, PM Small, C Larkin, SP Singh, P Kelly, MF Sierra, ...","Journal of Infectious Diseases 171 (1), 170-176",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11062267163806686416,69,1995
Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance,"A Altmann, N Beerenwinkel, T Sing, I Savenkov, M Däumer, R Kaiser, ...","Antiviral therapy 12 (2), 169",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15620339925795810545,67,2007
HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy,"R Kantor, LS Zijenah, RW Shafer, S Mutetwa, E Johnston, R Lloyd, ...","AIDS Research and Human retroviruses 18 (18), 1407-1413",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9873208707869244802,67,2002
Predictors of survival in HIV-infected tuberculosis patients.,"RW Shafer, AB Bloch, C Larkin, V Vasudavan, S Seligman, JD Dehovitz, ...","AIDS (London, England) 10 (3), 269-272",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12999695484494903695,66,1996
Whole-genome sequencing of the efficient industrial fuel-ethanol fermentative Saccharomyces cerevisiae strain CAT-1,"F Babrzadeh, R Jalili, C Wang, S Shokralla, S Pierce, A Robinson-Mosher, ...","Molecular genetics and genomics 287 (6), 485-494",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6167340732228198541,65,2012
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.,"RW Shafer, JA Eisen, TC Merigan, DA Katzenstein","Journal of virology 71 (7), 5441-5448",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2112657821152719533,65,1997
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing,"GL Melikian, SY Rhee, V Varghese, D Porter, K White, J Taylor, W Towner, ...","Journal of Antimicrobial Chemotherapy 69 (1), 12-20",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14297810418034080367,64,2013
Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays,"J Zhang, SY Rhee, J Taylor, RW Shafer","Journal of acquired immune deficiency syndromes (1999) 38 (4), 439",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2508546450304866992,64,2005
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy,"R Kantor, WJ Fessel, AR Zolopa, D Israelski, N Shulman, JG Montoya, ...","Antimicrobial agents and chemotherapy 46 (4), 1086-1092",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7452921723807301555,63,2002
Biomarker discovery using targeted maximum‐likelihood estimation: Application to the treatment of antiretroviral‐resistant HIV infection,"O Bembom, ML Petersen, SY Rhee, WJ Fessel, SE Sinisi, RW Shafer, ...","Statistics in medicine 28 (1), 152-172",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9777296350091426305,62,2009
Efavirenz-and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.,"NS Shulman, AR Zolopa, DJ Passaro, U Murlidharan, DM Israelski, ...","Journal of acquired immune deficiency syndromes (1999) 23 (3), 221-226",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3931548382939783423,62,2000
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation,"V Varghese, E Wang, F Babrzadeh, MH Bachmann, R Shahriar, T Liu, ...","PloS one 5 (6), e10992",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18415535164969510747,61,2010
Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first-and second-line antiretroviral treatment regimens,"GU Van Zyl, TF Liu, M Claassen, S Engelbrecht, T De Oliveira, W Preiser, ...","PloS one 8 (6), e67188","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16321572464936864299,4474091333550768768",60,2013
Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy,"AR Kallianpur, T Hulgan, JA Canter, MD Ritchie, JL Haines, GK Robbins, ...","Aids 20 (11), 1503-1513",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12585175422228251861,60,2006
HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing,"SY Rhee, MR Jordan, E Raizes, A Chua, N Parkin, R Kantor, GU Van Zyl, ...","PLoS One 10 (12), e0145772",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7122742017377030054,59,2015
Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database,"A Altmann, M Däumer, N Beerenwinkel, Y Peres, E Schülter, J Büch, ...","The Journal of infectious diseases 199 (7), 999-1006",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14840961786055351573,59,2009
Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype,"M Zazzi, L Romano, G Venturi, RW Shafer, C Reid, F Dal Bello, C Parolin, ...","Journal of Antimicrobial Chemotherapy 53 (2), 356-360",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11516230484030883985,58,2004
Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay,"A Kapoor, M Jones, RW Shafer, SY Rhee, P Kazanjian, EL Delwart","Journal of virology 78 (13), 7112-7123",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16626140866552761822,56,2004
Predictive value of HIV-1 genotypic resistance test interpretation algorithms,"SY Rhee, WJ Fessel, TF Liu, NM Marlowe, CM Rowland, RA Rode, ...","Journal of Infectious Diseases 200 (3), 453-463",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7796825817950127537,54,2009
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations,"EC Reuman, SY Rhee, SP Holmes, RW Shafer","Journal of antimicrobial chemotherapy 65 (7), 1477-1485",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=800845205794541139,53,2010
"Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma.","RW Shafer, DJ Levee, MA Winters, KL Richmond, D Huang, TC Merigan","Journal of clinical microbiology 35 (2), 520-522",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3375228573786109314,53,1997
Prediction of response to antiretroviral therapy by human experts and by the EuResist data‐driven expert system (the EVE study),"M Zazzi, R Kaiser, A Sönnerborg, D Struck, A Altmann, M Prosperi, ...","HIV medicine 12 (4), 211-218",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15340782170914873001,50,2011
"HIV-1 protease, reverse transcriptase, and integrase variation","SY Rhee, K Sankaran, V Varghese, MA Winters, CB Hurt, JJ Eron, ...","Journal of virology 90 (13), 6058-6070",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=834340334449835539,49,2016
Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment,"Y Mitsuya, TF Liu, SY Rhee, WJ Fessel, RW Shafer","The Journal of infectious diseases 196 (8), 1177-1179",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15527907317700790946,49,2007
Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery,"SY Rhee, S Margeridon-Thermet, MH Nguyen, TF Liu, RM Kagan, ...","Antiviral research 88 (3), 269-275",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13068202797381743823,48,2010
Synonymous–non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN),"MJ Gonzales, JM Dugan, RW Shafer","Bioinformatics 18 (6), 886-887",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1510060557187828564,48,2002
Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.,"M Holodniy, D Katzenstein, M Winters, J Montoya, R Shafer, M Kozal, ...","Journal of acquired immune deficiency syndromes 6 (4), 366-369",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6104277437927799836,48,1993
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe,"RW Shafer, TK Chuang, P Hsu, CB White, DA Katzenstein","AIDS research and human retroviruses 15 (1), 65-69",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9349836442299204791,46,1999
Drug resistance and antiretroviral drug development,"RW Shafer, JM Schapiro","Journal of Antimicrobial Chemotherapy 55 (6), 817-820",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3333190734374248748,45,2005
HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe,"PC Tien, RW Shafer, CH Contag, DA Katzenstein, M Batra","AIDS research and human retroviruses 16 (10), 973-979",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13146823536998376231,45,2000
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility,"GL Melikian, SY Rhee, J Taylor, WJ Fessel, D Kaufman, W Towner, ...","Antimicrobial agents and chemotherapy 56 (5), 2305-2313","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17510064264083217867,4561615934687322671",43,2012
"Comparison of the mechanisms of drug resistance among HIV, hepatitis B, and hepatitis C","S Margeridon-Thermet, RW Shafer","Viruses 2 (12), 2696-2739",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6352905306199669169,43,2010
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors,"K Deforche, R Camacho, Z Grossman, T Silander, MA Soares, Y Moreau, ...","Infection, genetics and evolution 7 (3), 382-390",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5933768688510267320,43,2007
Human immunodeficiency virus drug resistance: 2018 recommendations of the international antiviral society–USA panel,"HF Günthard, V Calvez, R Paredes, D Pillay, RW Shafer, AM Wensing, ...","Clinical Infectious Diseases 68 (2), 177-187",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=733080048772472198,42,2018
Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA,"LM Demeter, R D'Aquila, O Weislow, E Lorenzo, A Erice, J Fitzgibbon, ...","Journal of virological methods 75 (1), 93-104",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6243709553828654759,42,1998
"HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.","MJ Kozal, RW Shafer, MA Winters, DA Katzenstein, E Aguiniga, J Halpern, ...","Journal of acquired immune deficiency syndromes 7 (8), 832-838",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3682924883660576795,41,1994
Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions.,"RW Shafer, PA Seitzman, ML Tapper","Journal of acquired immune deficiency syndromes 2 (4), 389-393",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18205161667645622978,41,1989
Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations,"R Shahriar, SY Rhee, TF Liu, WJ Fessel, A Scarsella, W Towner, ...","Antimicrobial agents and chemotherapy 53 (11), 4869-4878",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6760703527755155498,40,2009
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.,"NS Shulman, RA Machekano, RW Shafer, MA Winters, AR Zolopa, ...","Journal of acquired immune deficiency syndromes (1999) 27 (4), 377-380",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13520518642058367944,40,2001
"Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy) ethyl] adenine, and 9-[2-(phosphonylmethoxy) propyl] adenine against drug-susceptible and drug …","S Palmer, RW Shafer, TC Merigan","Antimicrobial agents and chemotherapy 43 (8), 2046-2050",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10639688521070904875,37,1999
African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy,"JA Canter, GK Robbins, D Selph, DB Clifford, AR Kallianpur, R Shafer, ...","The Journal of infectious diseases 201 (11), 1703-1707",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9176686191828096445,36,2010
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients,"NS Shulman, MD Hughes, MA Winters, RW Shafer, AR Zolopa, ...","J Acquir Immune Defic Syndr 31 (2), 121-127",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4981966735092466174,36,2002
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching,"JH Elliott, L Lynen, A Calmy, A De Luca, RW Shafer, M Zolfo, B Clotet, ...","Aids 22 (16), 2053-2067",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14488961674026331783,35,2008
Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity,"R Gifford, T de Oliveira, A Rambaut, RE Myers, CV Gale, D Dunn, ...","Aids 20 (11), 1521-1529",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10362707340733162940,35,2006
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors,"AE Basson, SY Rhee, CM Parry, Z El-Khatib, S Charalambous, ...","Antimicrobial agents and chemotherapy 59 (2), 960-971",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3170243185335305243,34,2015
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries …,"MW Tang, SY Rhee, S Bertagnolio, N Ford, S Holmes, KC Sigaloff, ...","The Journal of infectious diseases 207 (suppl_2), S70-S77",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1729166291810737863,34,2013
Public database for HIV drug resistance in southern Africa,"T de Oliveira, RW Shafer, C Seebregts","Nature 464 (7289), 673",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5171523301792039217,34,2010
Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options,RW Shafer,"The Journal of infectious diseases 199 (5), 610-612",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5189212099994003657,34,2009
Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1,"Y Koh, M Aoki, ML Danish, H Aoki-Ogata, M Amano, D Das, RW Shafer, ...","Journal of virology 85 (19), 10079-10089",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16652348502269091651,32,2011
"ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy","MF Para, P Meehan, J Holden-Wiltse, M Fischl, G Morse, R Shafer, ...","Antimicrobial agents and chemotherapy 43 (6), 1373-1378",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9274055820635333556,32,1999
Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse …,"RW Shafer, MA Winters, AK Iversen, TC Merigan","Antimicrobial agents and chemotherapy 40 (12), 2887-2890",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4610341341399805562,32,1996
More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1,"AF Feder, SY Rhee, SP Holmes, RW Shafer, DA Petrov, PS Pennings","Elife 5, e10670",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7279635759399042122,31,2016
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan …,"J Gregson, P Kaleebu, VC Marconi, C van Vuuren, N Ndembi, RL Hamers, ...","The Lancet infectious diseases 17 (3), 296-304",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6130323356638254126,29,2017
Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment,"S Margeridon-Thermet, ES Svarovskaia, F Babrzadeh, R Martin, TF Liu, ...","Antimicrobial agents and chemotherapy 57 (1), 343-349",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14247680780106736316,29,2013
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1,"LM Smeaton, V DeGruttola, GK Robbins, RW Shafer","Controlled clinical trials 22 (2), 142-159",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10209379861392989199,29,2001
Bayesian network analyses of resistance pathways against efavirenz and nevirapine,"K Deforche, RJ Camacho, Z Grossman, MA Soares, K Van Laethem, ...","AIDS (London, England) 22 (16), 2107",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10265277639105727891,28,2008
A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses,"AN Kolomeets, V Varghese, P Lemey, MR Bobkova, RW Shafer","AIDS (London, England) 28 (17), F1",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1896262272218179893,27,2014
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure,"Y Mitsuya, MA Winters, WJ Fessel, SY Rhee, L Hurley, M Horberg, ...","AIDS Research & Human Retroviruses 22 (12), 1300-1305",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5704883092402783396,27,2006
Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and D,"SH Eshleman, MJ Gonzales, G Becker-Pergola, SC Cunningham, ...","AIDS research and human retroviruses 18 (7), 507-511",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2078611172538607648,27,2002
Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals,"RW Shafer, A Warford, MA Winters, MJ Gonzales","Journal of virological methods 86 (2), 143-153",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13734509796591436880,27,2000
"Transmitted HIV drug resistance is high and longstanding in metropolitan Washington, DC","SG Kassaye, Z Grossman, M Balamane, B Johnston-White, C Liu, ...","Clinical Infectious Diseases 63 (6), 836-843",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1129988028742877682,26,2016
HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir,"V Varghese, TF Liu, SY Rhee, P Libiran, C Trevino, WJ Fessel, RW Shafer","AIDS research and human retroviruses 26 (12), 1323-1326",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11496260876143279595,26,2010
Data-adaptive selection of the adjustment set in variable importance estimation,"O Bembom, JW Fessel, RW Shafer, MJ van der Laan",bepress,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13325858058641862078,26,2008
Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep …,"S Margeridon-Thermet, S Le Pogam, L Li, TF Liu, N Shulman, RW Shafer, ...","PloS one 9 (8), e105569",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10462591900309706939,25,2014
Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector,"EC Reuman, MH Bachmann, V Varghese, WJ Fessel, RW Shafer","Antimicrobial agents and chemotherapy 54 (2), 934-936",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2820581188338477444,25,2010
Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations,"MA Winters, RM Lloyd Jr, RW Shafer, MJ Kozal, MD Miller, M Holodniy","PloS one 7 (7), e40514",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2108212645539863279,24,2012
Sequence editing by apolipoprotein B RNA-editing catalytic component-B and epidemiological surveillance of transmitted HIV-1 drug resistance,"RJ Gifford, SY Rhee, N Eriksson, TF Liu, M Kiuchi, AK Das, RW Shafer","AIDS (London, England) 22 (6), 717",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6985570029911663762,24,2008
Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir+ emtricitabine/lamivudine+ efavirenz …,"JL Blanco, JSG Montaner, VC Marconi, MM Santoro, AE Campos-Loza, ...","Aids 28 (17), 2531-2539",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8217184024613707494,23,2014
Virologic efficacy of boosted double versus boosted single protease inhibitor therapy,"ML Petersen, Y Wang, MJ van der Laan, SY Rhee, RW Shafer, WJ Fessel","AIDS (London, England) 21 (12), 1547",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10286764218392905485,23,2007
Surveillance of HIV transmitted drug resistance in Latin America and the Caribbean: a systematic review and meta-analysis,"S Avila-Rios, O Sued, SY Rhee, RW Shafer, G Reyes-Teran, G Ravasi","PloS one 11 (6), e0158560",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17044154735607239494,22,2016
The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment,"WJ Fessel, B Anderson, SE Follansbee, MA Winters, ST Lewis, ...","Antiviral research 92 (3), 484-487",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12280926274104615948,22,2011
"Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates …","A Talbot, P Grant, J Taylor, JG Baril, TF Liu, H Charest, B Brenner, ...","Antimicrobial agents and chemotherapy 54 (6), 2473-2479",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4774661312970750638,22,2010
Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations,"E Johnston, KM Dupnik, MJ Gonzales, MA Winters, SY Rhee, T Imamichi, ...","AIDS (London, England) 19 (7), 731",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7797565428489863695,22,2005
Prototypical recombinant multi-protease-inhibitor-resistant infectious molecular clones of human immunodeficiency virus type 1,"V Varghese, Y Mitsuya, WJ Fessel, TF Liu, GL Melikian, DA Katzenstein, ...","Antimicrobial agents and chemotherapy 57 (9), 4290-4299",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10885059187308129405,21,2013
Algorithm specification interface for human immunodefiency virus type 1 genotypic interpretation,"BJ Betts, RW Shafer","journal of clinical microbiology 41 (6), 2792-2794",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7074327438898605693,21,2003
A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes,"KM Doherty, P Nakka, BM King, SY Rhee, SP Holmes, RW Shafer, ...","BMC bioinformatics 12 (1), 477",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5552186099108713135,20,2011
A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads,"EC Reuman, S Margeridon-Thermet, HB Caudill, T Liu, K Borroto-Esoda, ...","Bioinformatics 26 (23), 2929-2932",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2441943380754508611,20,2010
Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study,"T Hulgan, M Hughes, X Sun, LM Smeaton, E Terry, GK Robbins, ...","JAIDS Journal of Acquired Immune Deficiency Syndromes 42 (4), 450-454",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14770490800210299141,19,2006
Modifying antiretroviral therapy in virologically suppressed HIV-1-infected patients,"SE Collins, PM Grant, RW Shafer","Drugs 76 (1), 75-98",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14795306489001974999,18,2016
Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype,"A Altmann, T Sing, H Vermeiren, B Winters, E Van Craenenbroeck, ...","Antiviral Therapy 14 (2), 273-283",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12071738466412448297,18,2009
Educational attainment and response to HAART during initial therapy for HIV-1 infection,"LG Marc, MA Testa, AM Walker, GK Robbins, RW Shafer, NB Anderson, ...","Journal of psychosomatic research 63 (2), 207-216",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14897257991671776968,18,2007
Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing,"MJ Gonzales, E Johnson, KM Dupnik, T Imamichi, RW Shafer","Journal of acquired immune deficiency syndromes (1999) 34 (4), 398",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7114522365820463999,18,2003
Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration,"SY Rhee, V Varghese, SP Holmes, GU Van Zyl, K Steegen, MA Boyd, ...","EBioMedicine 18, 225-235",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17646612541633360041,17,2017
Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS Clinical Trials Group Study 384,"BJ Grady, DC Samuels, GK Robbins, D Selph, JA Canter, RB Pollard, ...","Journal of acquired immune deficiency syndromes (1999) 58 (4), 363",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6842652440347017506,17,2011
HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL,"Y Mitsuya, MA Winters, WJ Fessel, SY Rhee, S Slome, J Flamm, ...","Journal of acquired immune deficiency syndromes (1999) 43 (1), 56",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16059983475412024946,17,2006
The challenge of antiretroviral drug resistance in HIV-1-infected childre,RW Shafer,"Jornal de pediatria 85 (2), 91-94",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7135572883633606445,16,2009
Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates,"RW Shafer, MJ Kozal, DA Katzenstein, WH Lipil, IF Johnstone, ...","Journal of virological methods 41 (3), 297-310",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4804043331320635338,16,1993
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores,"P Grant, EC Wong, R Rode, R Shafer, A De Luca, J Nadler, T Hawkins, ...","Antimicrobial agents and chemotherapy 52 (11), 4050-4056",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9381602631937682804,15,2008
"Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside …","PF Smith, GK Robbins, RW Shafer, H Wu, S Yu, MS Hirsch, TC Merigan, ...","Antimicrobial agents and chemotherapy 49 (8), 3558-3561",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9892259513094617795,15,2005
Comparison of an in vitro diagnostic next-generation sequencing assay with Sanger sequencing for HIV-1 genotypic resistance testing,"PL Tzou, P Ariyaratne, V Varghese, C Lee, E Rakhmanaliev, C Villy, ...","Journal of clinical microbiology 56 (6), e00105-18",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16171250359140862675,14,2018
Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1–Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing,"DS Clutter, S Zhou, V Varghese, SY Rhee, BA Pinsky, W Jeffrey Fessel, ...","The Journal of infectious diseases 216 (3), 387-391",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16489754495941284321,14,2017
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease,"JE Foulkes-Murzycki, C Rosi, N Kurt Yilmaz, RW Shafer, CA Schiffer","ACS chemical biology 8 (3), 513-518",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=983363728382978326,14,2012
NO DETECTION OF VARIANTS BEARING NS5B S282T MERICITABINE (MCB) RESISTANCE MUTATION IN DAA TREATMENT-NAIVE HCV GENOTYPE 1 (G1)-INFECTED PATIENTS USING ULTRA-DEEP PYROSEQUENCING …,"S Margeridon, S Le Pogam, T Liu, B Hanczaruk, B Simen, N Shulman, ...",Hepatology 54 (4),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4989520737754323465,14,2011
"Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance","E Johnston, MA Winters, SY Rhee, TC Merigan, CA Schiffer, RW Shafer","Antimicrobial agents and chemotherapy 48 (12), 4864-4868",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8580644776930331234,14,2004
A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates,"RM Jellinger, RW Shafer, TC Merigan","Journal of Infectious Diseases 175 (3), 561-566",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4698697707325357061,14,1997
Human immunodeficiency virus type 1 drug resistance mutations update,RW Shafer,"The Journal of infectious diseases 216 (suppl_9), S843-S846",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1109052307057357015,13,2017
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation,"R Paredes, PL Tzou, G Van Zyl, G Barrow, R Camacho, S Carmona, ...","PLoS One 12 (7), e0181357",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14905654698213549736,13,2017
Genetic variability of HIV-1 for drug resistance assay development,"D Clutter, P Sánchez, SY Rhee, R Shafer","Viruses 8 (2), 48",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7358826091354918044,13,2016
Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape,"K Theys, K Deforche, G Beheydt, Y Moreau, K Van Laethem, P Lemey, ...","BMC bioinformatics 11 (1), 409",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13515875274177352534,13,2010
"Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)","AR Zolopa, LC Lazzeroni, A Rinehart, FB Vezinet, F Clavel, A Collier, ...","Clinical infectious diseases 41 (1), 92-99",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5596844227034819987,13,2005
Jar,"WR Drummond, RJ Moore","US Patent App. 07/937,660",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15956616856623059620,13,1994
"Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine","M Balamane, V Varghese, GL Melikian, WJ Fessel, DA Katzenstein, ...","Antimicrobial agents and chemotherapy 56 (8), 4522-4524",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13267700435311312793,12,2012
A combined data mining approach for infrequent events: analyzing HIV mutation changes based on treatment history,"RS Lin, SY Rhee, RW Shafer, AK Das","Computational Systems Bioinformatics, 385-388",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6160653073548559685,12,2006
Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy,"RW Shafer, MA Winters, RM Jellinger, TC Merigan","Journal of Infectious Diseases 174 (2), 448-449",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2427893924589217232,12,1996
Delavirdine (DLV) susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy,"LM Demeter, RW Shafer, M Para, G Morse, W Freimuth, TC Merigan, ...",JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 10 …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18150182392056703096,12,1995
Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid,"RW Shafer, WD Jones","Tubercle 72 (2), 149-151",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15674067191467223459,12,1991
Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance in a Large US Clinic Population.,"SY Rhee, D Clutter, WJ Fessel, D Klein, S Slome, BA Pinsky, JL Marcus, ...",Clin. infect. dis,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14705899622957824734,11,2018
Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384,"PD Leger, DH Johnson, GK Robbins, RW Shafer, DB Clifford, J Li, ...","Journal of neurovirology 20 (3), 304-308",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1918809251406474322,11,2014
In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis,"BA Rath, KP Yousef, DK Katzenstein, RW Shafer, C Schütte, M von Kleist, ...","PLoS One 8 (4), e61102",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3013423992343567518,11,2013
Protease and reverse transcriptase mutation patterns in HIV type 1 isolates from heavily treated persons: comparison of isolates from Northern California with isolates from …,"MJ Gonzales, I Belitskaya, KM Dupnik, SY Rhee, RW Shafer","AIDS research and human retroviruses 19 (10), 909-915",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5197270305258381715,11,2003
Human immunodeficiency virus on the Web: a guided tour,"RW Shafer, SC Deresinski","Clinical infectious diseases 31 (2), 568-577",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13042121689909757201,10,2000
Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical …,"RW Shafer, MA Winters, DL Mayers, AJ Japour, DR Kuritzkes, ...","Journal of clinical microbiology 34 (7), 1849-1853",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14289029420602486861,10,1996
"Site nurse–initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: Substudy of ACTG 384","GK Robbins, MA Testa, M Su, SA Safren, G Morse, S Lammert, RW Shafer, ...","HIV clinical trials 14 (5), 235-253",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1665933555965481978,9,2013
Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions,"R Kantor, AP Carvalho, B Wynhoven, MA Soares, P Cane, J Clarke, ...","Antiviral Therapy 8 (3), U58-U59",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11818139887267592746,9,2003
HIV virology for clinical trials.,"RW Shafer, TC Merigan","AIDS (London, England) 9, S193",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14225832165235724975,9,1995
HIV-1 transmission networks in a small world,"PS Pennings, SP Holmes, RW Shafer","The Journal of infectious diseases 209 (2), 180",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7639134463165175211,8,2014
Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance,"F Babrzadeh, V Varghese, M Pacold, TF Liu, P Nyrén, C Schiffer, ...","Journal of Antimicrobial Chemotherapy 68 (2), 414-418",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1244973324237817037,8,2012
Response to Therapy in Antiretroviral Therapy–Naive Patients With Isolated Nonnucleoside Reverse Transcriptase Inhibitor–Associated Transmitted Drug Resistance,"DS Clutter, WJ Fessel, SY Rhee, LB Hurley, DB Klein, JPA Ioannidis, ...","Journal of acquired immune deficiency syndromes (1999) 72 (2), 171",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5734697742284475396,7,2016
Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays,"NS Shulman, J Delgado, RJ Bosch, MA Winters, E Johnston, RW Shafer, ...","JAIDS Journal of Acquired Immune Deficiency Syndromes 39 (1), 78-81",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16297088775693011163,7,2005
Quantitative analysis of syncytium-inducing and non-syncytium-inducing virus in patients infected with human immunodeficiency virus type 1.,"RW Shafer, E Aguiniga, TC Merigan","Journal of clinical microbiology 33 (1), 212-214",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6544368571970605783,7,1995
"Moderate-to-high levels of pretreatment HIV drug resistance in KwaZulu-Natal Province, South Africa","B Chimukangara, ABM Kharsany, RJ Lessells, K Naidoo, SY Rhee, ...","AIDS research and human retroviruses 35 (2), 129-138",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15799816333031182606,6,2019
Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population,"SY Rhee, D Clutter, WJ Fessel, D Klein, S Slome, BA Pinsky, JL Marcus, ...","Clinical Infectious Diseases 68 (2), 213-221",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2111662929007555109,6,2018
Evolution of gag and gp41 in patients receiving ritonavir-boosted protease inhibitors,"J Manasa, V Varghese, SLK Pond, SY Rhee, PL Tzou, WJ Fessel, ...","Scientific reports 7 (1), 11559",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7320128243371701900,6,2017
Evaluation of the Aptima HIV-1 Quant Dx Assay using plasma and dried blood spots,"MK Sahoo, V Varghese, E White, M Winslow, DA Katzenstein, RW Shafer, ...","Journal of clinical microbiology 54 (10), 2597-2601",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7932122397549667309,6,2016
Reverse transcriptase and protease sequence evolution in two HIV-1-infected couples,"S Palmer, D Vuitton, MJ Gonzales, A Bassignot, RW Shafer","Journal of acquired immune deficiency syndromes (1999) 31 (3), 285",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1645519631106294589,6,2002
"Trends in pretreatment HIV-1 drug resistance in antiretroviral therapy-naive adults in South Africa, 2000–2016: a pooled sequence analysis","B Chimukangara, RJ Lessells, SY Rhee, J Giandhari, ABM Kharsany, ...","EClinicalMedicine 9, 26-34",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17113518420707078975,5,2019
"Q148N, a novel integrase inhibitor resistance mutation associated with low-level reduction in elvitegravir susceptibility","V Varghese, BA Pinsky, DS Smith, D Klein, RW Shafer","AIDS research and human retroviruses 32 (7), 702-704",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18039993206413019704,5,2016
Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient-and Sequence-Level …,"SY Rhee, JL Blanco, MR Jordan, J Taylor, P Lemey, V Varghese, ...","PLoS Med 12 (6), e1001845",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17680574884785542911,5,2015
"Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes","SY Rhee, JL Blanco, TF Liu, I Pere, R Kaiser, M Zazzi, F Incardona, ...","AIDS research and therapy 9 (1), 13",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15369262498568120893,5,2012
ULTRA-DEEP SEQUENCING OF THE NS3 AND NS5B REGIONS DETECTS PRE-EXISTING RESISTANT VARIANTS TO DIRECT ACTING ANTIVIRALS (DAA) IN HCV GENOTYPE 1 INFECTED PATIENTS NAïVE: 819,"S Margeridon, S Le Pogam, T Liu, B Hanczaruk, T Arnold, B Simen, ...",Hepatology 52,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14818331009521211404,5,2010
Virological response to antiretroviral therapy in the setting of the K65R mutation,"AB Nevins, M Wirden, SY Rhee, J Taylor, WJ Fessel, M Horberg, ...","Antiviral Therapy 11 (5), S92-S92",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9213704952110764820,5,2006
Stanford HIV drug resistance database,RW Shafer,Available in: http://hivdb. stanford. edu (accessed in 2003),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10628774295400174744,5,2004
New virologic tools for the design and analysis of clinical trials,"RW Shafer, TC Merigan","Journal of Infectious Diseases 171 (5), 1325-1328",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15980734126531988201,5,1995
Prevalence of HIV-1 syncytium-inducing phenotype,"MJ Kozal, RV Ramachandran, RW Shafer","Annals of internal medicine 120 (9), 811-811",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=207779308055889118,5,1994
T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384,"T Hulgan, GK Robbins, SA Kalams, DC Samuels, B Grady, R Shafer, ...","PloS one 7 (8), e43803",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3551868101709755389,4,2012
Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients,"A Kapoor, B Shapiro, RW Shafer, N Shulman, SY Rhee, EL Delwart","Retrovirology 5 (1), 7",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9824013533534459099,4,2008
Concordance of HIV drug resistance genotyping results for paired PBMC and plasma specimens from persons newly diagnosed with HIV,"DE Bennett, MA Winters, RW Shafer, W Heneine, L McCormick, ...","ANTIVIRAL THERAPY 10 (4), S176-S176",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6805972020994465584,4,2005
Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens,"SC Inzaule, RL Hamers, M Doherty, RW Shafer, S Bertagnolio, ...",The Lancet Infectious Diseases,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2064703326951780057,3,2019
"Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the ","D Akaberi, A Bergfors, M Kjellin, N Kameli, L Lidemalm, B Kolli, ...","Infection ecology & epidemiology 8 (1), 1528117",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9720595524188990462,3,2018
NucAmino: a nucleotide to amino acid alignment optimized for virus gene sequences,"PL Tzou, X Huang, RW Shafer","BMC bioinformatics 18 (1), 138",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1215712096662689816,3,2017
2015 update of the drug resistance mutations in HIV-1,"AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...","Topics in antiviral medicine 23 (4), 132-141",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7101260016974111123,3,2015
Mechanisms of resistance to antiviral agents,"RW Shafer, I Najera, S Chou","Manual of Clinical Microbiology, 10th Edition, 1710-1728",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12995619936473311625,3,2011
"Drug susceptibility profile of OBP-601, a novel NRTI, using a comprehensive panel of NRTI-or NNRTI-resistant viruses","J Weber, J Weberova, A Vazquez, Y Urata, T Matsuda, R Shafer, E Arts, ...","Abstract 726b, 15th CROI",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18105581060789621091,3,2008
Knowledge integration of software for HIV drug resistance research,"G Hernandez Jr, SY Rhee, RW Shafer, AK Das",AMIA Annu. Symp. Proc 973,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10548644945160466147,3,2007
Prediction of HIV mutation changes based on treatment history.,"RS Lin, SY Rhee, RW Shafer, AK Das","AMIA... Annual Symposium proceedings. AMIA Symposium 2006, 1011-1011",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5422361833226943015,3,2006
Real-time PCR assays identify transmitted drug-resistant HIV-1 previously undetected by conventional nucleotide sequencing,"JA Johnson, JF Li, D Bennett, M Cong, T Spira, RW Shafer, T Gleeson, ...","ANTIVIRAL THERAPY 9 (4), U69-U69",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9501366210380489907,3,2004
Surveillance of anti-tubercular drug resistance.,"G GC, B Rijal, AP Sharma","Journal of Nepal medical association 41 (142), 311-313",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11398344276458595916,3,2002
The clinical implications of pretreatment drug resistance--a moving target,"RW Shafer, LM Frenkel",Clin Infect Dis,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9393219908636316877,2,2018
Diff-seq: A high throughput sequencing-based mismatch detection assay for DNA variant enrichment and discovery,"D Aggeli, VO Karas, NA Sinnott-Armstrong, V Varghese, RW Shafer, ...","Nucleic acids research 46 (7), e42-e42",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10300829327227057243,2,2018
The Future of HIV-1 Therapeutics. Resistance is Futile?,RW Shafer,"Clinical Infectious Diseases 62 (1), 136-137",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12096818601849952971,2,2015
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility,"V Varghese, Y Mitsuya, R Shahriar, MH Bachmann, WJ Fessel, ...","Antimicrobial agents and chemotherapy 53 (5), 2196-2198",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4298088440763240206,2,2009
Ultra-deep pyrosequencing of minority variants in plasma samples from ARV-treated persons and from untreated persons with T215 revertants,"Y Mitsuya, C Wang, P Jayakumar, B Gharizadeh, M Ronaghi, RW Shafer","ANTIVIRAL THERAPY 12, S151-S151",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1619446317183191783,2,2007
HIV-1 RT and protease mutations for HIV-1 drug resistance surveillance and epidemiology: application to published studies of primary infection,RW Shafer,http://hivdb. stanford. edu,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13428366368712330356,2,2006
Comparative evaluation of the ViroSeq® v2. 6 interpretation algorithm for prediction of HIV-1 drug resistance from viral genotype,"N Marlowe, R Shafer, H Leong, T Liu, E Shulse, M Zoccoli","Hiv Medicine 5 (3), 239-240",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4459046117642952823,2,2004
REINFECTION WITH MULTIDRUG-RESISTANT TUBERCULOSIS-REPLY,"PM Small, RW Shafer, GK Schoolnik","NEW ENGLAND JOURNAL OF MEDICINE 329 (11), 812-812",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5452100122506900978,2,1993
Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance Testing,"J Weber, I Volkova, MK Sahoo, PL Tzou, RW Shafer, BA Pinsky","The Journal of Molecular Diagnostics 21 (6), 961-970",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13336075396845497420,1,2019
Amino Acid Prevalence of HIV-1 ,"PL Tzou, SY Rhee, RW Shafer","AIDS research and human retroviruses 35 (10), 924-929",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=850808241452463846,1,2019
Multiplex Solid-Phase Melt Curve Analysis for the Point-of-Care Detection of HIV-1 Drug Resistance,"DS Clutter, G Mazarei, R Sinha, J Manasa, J Nouhin, E LaPrade, ...","The Journal of Molecular Diagnostics 21 (4), 580-592","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4606086189887553265,15558841548334523197",1,2019
"Resistance Testing for Integrase Strand Transfer Inhibitors in Naive, Human Immunodeficiency Virus-infected Individuals Reply","HF Gunthard, V Calvez, R Paredes, D Pillay, RW Shafer, AM Wensing, ...","CLINICAL INFECTIOUS DISEASES 68 (11), 1977-1978",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12662975068321087134,1,2019
More efficacious drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1,"AF Feder, SY Rhee, RW Shafer, DA Petrov, PS Pennings","bioRxiv, 024109",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=450813712448556706,1,2015
541 HIV Rebound Kinetics and CD4+ T-Cell Loss after Treatment Interruption: A Pooled Analysis of Six AIDS Clinical Trials Group (ACTG) Studies,"J Li, E Aga, R Bosch, J Mellors, D Kuritzkes, M Para, R Gandhi","Open forum infectious diseases 1 (suppl_1), S23-S23",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11044215762287411008,1,2014
HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure,"RZ Sangeda, K Theys, G Beheydt, SY Rhee, K Deforche, J Vercauteren, ...","Infection, Genetics and Evolution 19, 349-360",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12008981640849224518,1,2013
Assessing the WHO recommended first-line ART regimens for resource-limited settings: Comparing the relative virologic efficacy and resistance patterns of TDF/3TC/NVP to AZT/3TC …,"JC Karasi, F Musonera, K Iranyumviye, JY Servais, C Devaux, ...","Journal of the International AIDS Society 15, 55-55",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17438175447690302597,1,2012
Minority Variants Associated with Transmitted and Acquired HIV-1 Non-Nucleoside RT Inhibitor (NNRTI) Resistance: Implications for the Use of Second Generation NNRTIs,"RS Vici Varghese, SY Rhee, T Liu, BB Simen, M Egholm, B Hanczaruk, ...","Journal of acquired immune deficiency syndromes (1999) 52 (3), 309",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7364039644407997550,1,2009
Minority drug resistance mutations associated with the NNRTI mutation K103N in ARV-naive and NNRTI-treated HIV-1-infected patients,"V Varghese, R Shahriar, SY Rhee, BB Simen, M Egholm, B Gharizadeh, ...","ANTIVIRAL THERAPY 14 (4), A143-A143",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17428949026461999958,1,2009
"Genotypic, phenotypic and virtual phenotypic resistance patterns for darunavir and tipranavir: an independent analysis of a Québec HIV-1 cohort highly resistant to all other …","A Talbot, P Grant, J Taylor, JG Baril, H Charest, TF Liu, B Brenner, ...","ANTIVIRAL THERAPY 14 (4), A128-A128",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3207016126689920698,1,2009
Inferring virological response from genotype: with or without predicted phenotypes,"A Altmann, T Sing, H Vermeiren, B Winters, E Van Craenenbroeck, ...","Antivir Ther 12, S169",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1067806401364695419,1,2007
Case Files From Stanford University Medical Center: Drug Resistance Testing in Previously Untreated Patients With HIV–Knowing What to Look for and Choosing Appropriate Therapy,"RW Shafer, DP Nguyen, WJ Fessel","Medscape General Medicine 8 (3), 32",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3442071906394401223,1,2006
N88D facilitates the development of multidrug resistance following nelfinvair treatment failure,"MA Winters, SY Rhee, M Horberg, A Scarsella, A Zolopa, SY Lee, ...","ANTIVIRAL THERAPY 10 (4), S110-S110",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=544767556139691023,1,2005
Virological response to antiretroviral therapy in the setting of the K65R mutation,"AB Nevins, SY Rhee, WJ Fessel, M Horberg, A Scarsella, SY Lee, ...","ANTIVIRAL THERAPY 10, S18-S18",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3758561376777980358,1,2005
Probabilistic graphical models for prediction of HIV-1 drug resistance mutations based on antiretroviral treatment history,"J Ravela, R Raina, SY Rhee, JM Schapiro, RW Shafer","Antiviral Therapy 9 (4), U90-U91",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6377874823344097713,1,2004
A systematic approach to identify mutations that can be used in epidemiological studies on transmission of drug resistant HIV,"D van de Vijver, B Brenner, D Turner, P Sandstrom, D Dunn, H Green, ...",Hiv Medicine 5 (3),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13485462590427118318,1,2004
Comparison of regimens as initial therapy for HIV,B Clotet,The New England journal of medicine 350 (10),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9861309706420463908,1,2004
Combination therapy of HIV-1 infection with nucleoside analog reverse transcriptase inhibitors,"RW Shafer, TC Merigan","Anti-HIV nucleosides: past, present and future. Austin, TX: RG Landes …",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12590861639335025977,1,1997
In vitro analysis of doravirine activity on HIV-1 clones harboring multiple NNRTI resistance mutations,"F Saladini, F Giammarino, A Giannini, A Boccuto, F Dragoni, I Vicenti, ...","HIV MEDICINE 20, 17-18",,0,2019
HIV-1 viral load is elevated in individuals with reverse transcriptase mutation M184V/I during virological failure of first line antiretroviral therapy and is associated with …,"R Gupta, J GREGSON, SOOYON RHEE, R DATIR, D PILLAY, C PERNO, ...",Oxford University Press,,0,2019
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance,"PL Tzou, SY Rhee, D Descamps, DS Clutter, B Hare, O Mor, M Grude, ...","Journal of Antimicrobial Chemotherapy 75 (1), 170-182",,0,2019
A systematic review of the genetic mechanisms of dolutegravir resistance,"SY Rhee, PM Grant, PL Tzou, G Barrow, PR Harrigan, JPA Ioannidis, ...","Journal of Antimicrobial Chemotherapy 74 (11), 3135-3149",,0,2019
P198 Dolutegravir rollout and expected prevalence of pretreatment drug resistance to antiretroviral therapy among kenyan women,"H Duarte, E Enns, D Stauffer, R Shafer, E Bendavid","Sexually Transmitted Infections 95 (Suppl 1), A137-A138",,0,2019
National and International Dimensions of Human Immunodeficiency Virus-1 Sequence Clusters in a Northern California Clinical Cohort,"SY Rhee, BR Magalis, L Hurley, MJ Silverberg, JL Marcus, S Slome, ...","Open Forum Infectious Diseases 6 (4), ofz135",,0,2019
National and International Dimensions of HIV-1 Sequence Clusters in a Northern California Clinical Cohort,"SY Rhee, BR Magalis, L Hurley, MJ Silverberg, JL Marcus, S Slome, ...",Open Forum Infectious Diseases,,0,2019
Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences,"PL Tzou, SLK Pond, S Avila-Rios, SP Holmes, R Kantor, RW Shafer","bioRxiv, 831685",,0,2019
Reply to Ambrosioni et al,"HF Günthard, V Calvez, R Paredes, D Pillay, RW Shafer, AM Wensing, ...","Clinical Infectious Diseases 68 (11), 1977-1978",,0,2018
Geographically-stratified HIV-1 group M ,"SY Rhee, RW Shafer","Scientific data 5, 180148",,0,2018
Selection analyses of paired HIV-1 ,"PL Tzou, SY Rhee, SLK Pond, J Manasa, RW Shafer","Scientific data 5, 180147",,0,2018
Correction: More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1,"AF Feder, SY Rhee, SP Holmes, RW Shafer, DA Petrov, PS Pennings","eLife 6, e24879",,0,2017
Prevalence and Clinical Implications of Minority Variant (MV) Human Immunodeficiency Virus (HIV) Drug-Resistance Mutations (DRMs) in Antiretroviral (ARV)-Naive Patients With …,"D Clutter, S Zhou, V Varghese, SY Rhee, B Pinsky, WJ Fessel, D Klein, ...","Open Forum Infectious Diseases 3 (suppl_1), 2383",,0,2016
HIV-1 drug resistance and resistance testing,"RW Shafer, DS Clutter, S Bertagnolio, MR Jordan","Infection, genetics and evolution: journal of molecular epidemiology and …",,0,2016
Responses to First-Line Antiretroviral Therapy (ART) in Patients With Isolated NNRTI Transmitted Drug Resistance (TDR),"D Clutter, J Fessel, SY Rhee, D Klein, M Silverberg, R Shafer",Open Forum Infectious Diseases 2 (suppl_1),,0,2015
542A Unique Non-Nucleoside RT Inhibitor Resistance Mutation in Epidemic Russian Subtype A HIV-1 Strains,"A Kolomeets, R Shafer","Open forum infectious diseases 1 (Suppl 1), S23",,0,2014
Topics in Antiviral Medicine™,"ET Overton, CM Wyatt, RT Mitsuyasu, AM Wensing, V Calvez, ...",,,0,2014
HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitor Induced Selective Pressure in vitro,"B Rath, K Yousef, D Katzenstein, R Shafer, C Schütte, M von Kleist, ...",,,0,2013
Is there cross talk between HIV-1 5'RT drug resistance mutations (DRMs) and connection/RNase H (3'RT) mutations?,"SY Rhee, V Varghese, MA Winters, M Holodniy, RW Shafer","ANTIVIRAL THERAPY 18, A67-A67",,0,2013
THPDB0103,"JC Karasi, F Musonera, K Iranyumviye, JY Servais, C Devaux, ...",Journal of the International Aids Society 15,,0,2012
TUAB0303,"G van Zyl, M Claassen, S Engelbrecht, T de Oliveira, W Preiser, N Wood, ...",Journal of the International Aids Society 15,,0,2012
Front & Back Matter,"L Gürtler, J Eberle, S Sierra, H Walter, MW Tang, TF Liu, RW Shafer, ...",Intervirology 55 (2),,0,2012
"Author and Subject Index Vol. 55, No. 2, 2012","L Gürtler, J Eberle, S Sierra, H Walter, MW Tang, TF Liu, RW Shafer, ...","Intervirology 55 (2), 184-184",,0,2012
Track B Clinical Science,"T Kyrychenko, G Dubynska, T Koval, I Kaidashev, V Korshenko","Journal of the International AIDS Society 15, 3",,0,2012
Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor,"MA Winters, RM Lloyd Jr, RW Shafer, MJ Kozal, MD Miller",,,0,2012
MAJOR ARTICLES AND BRIEF REPORTS,"TP Flanigan, CG Beckwith, JL Blanco, V Varghese, SY Rhee, JM Gatell, ...",,,0,2011
LOW-LEVEL PERSISTENCE OF HBV DRUG RESISTANCE MUTATIONS IN PATIENTS WITH A PAST HISTORY OF LAMIVUDINE (LAM) TREATMENT: 373,"S Margeridon, E Svarovskaia, S Martin, T Liu, K Borroto-Esoda, R Shafer",Hepatology 52,,0,2010
Epidemiological fact sheet on HIV and AIDS: Core data on epidemiology and response.,"PD Potdar, BS Daswani, NJ Rane, RE Akhigbe, JO Bamidele, ...","International Journal of Virology 7 (1), 158-163",,0,2010
HIV-1 Integrase Sequence Variability in Antiretroviral NaÃ¯ ve Patients and in Triple-Class Experienced Patients Subsequently Treated with Raltegravir,"TF Liu, SY Rhee, P Libiran, C Trevino, WJ Fessel, RW Shafer","AIDS RESEARCH AND HUMAN RETROVIRUSES 26 (12), 1323-1326",,0,2010
O desafio da resistência à medicação antirretroviral em crianças infectadas pelo HIV-1,RW Shafer,"Jornal de pediatria 85 (2), 91",,0,2009
Virologic outcome associated with genotype-guided therapy in patients with transmitted HIV-1 drug resistance (TDR) between 2003 and 2006,"SY Rhee, WJ Fessel, TF Liu, I Hurley, D Klein, S Follansbee, J Flamm, ...","ANTIVIRAL THERAPY 14 (4), A62-A62",,0,2009
"Sequence editing by Apolipoprotein B RNA-editing catalytic component and epidemiological surveillance of transmitted HIV-1 drug resistance?(vol 22, pg 717, 2008)","RJ Gifford, SY Rhee, N Eriksson, TF Liu, M Kiuchi, AK Das, RW Shafer","AIDS 22 (16), 2225-2225",,0,2008
Minority Human Immunodeficiency Virus,"RW Shafer, M Ronaghi, D Klein, WJ Fessel, SP Holmes, P Jayakumar, ...","J. Virol 82 (21), 10747",,0,2008
Case Files From Stanford University Medical Center: Ten Years of HAART: A Long Wait for Full HIV Suppression,"N Shulman, RW Shafer","Medscape General Medicine 9 (1), 10",,0,2007
"Prediction, of antiretroviral (ARV) treatment outcome using clinical variables plus genotype (GSS) versus a genotype modeled on past ARV treatment","SY Rhee, T Liu, WJ Fessel, AR Zolopa, JM Schapiro, RW Shafer","ANTIVIRAL THERAPY 11 (5), S178-S178",,0,2006
Replicative fitness of a panel of prototypical HIV-1 containing multiple NRTI-resistance mutations,"J Weber, M Mirza, O Jegede, J Weberova, RW Shafer, ...","ANTIVIRAL THERAPY 11 (5), S48-S48",,0,2006
Antiretroviral rounds. Virologic failure: true or false?,"JE Gallant, R Shafer","AIDS clinical care 17 (9), 84-85",,0,2005
The HIV‐1 Non‐subtype B Workgroup,"R Kantor, R Shafer, D Katzenstein",Journal of the International Aids Society 7 (1),,0,2005
Previously unclassified mutations at positions experienced treatment failure associated with antiretroviral drug resistance,"SY Rhee, L Hurley, A Zolopa, WJ Fessel, DP Nguyen, S Slome, S Smith, ...","ANTIVIRAL THERAPY 9 (4), U109-U110",,0,2004
The association of K65R with Q151M complex and the relationship to antiretroviral treatment: results from a northern California clinic population,"AR Zolopa, SY Rhee, D Shin, L Hurley, WJ Fessel, RW Shafer","ANTIVIRAL THERAPY 9 (4), U72-U72",,0,2004
Non-nucleoside reverse transcriptase inhibitor hypersusceptibility can be demonstrated in multicycle phenotype assays and in inhibition assays of purified HIV-1 reverse …,"NS Shulman, J Delgado, MA Winters, E Johnston, DA Katzenstein, ...","ANTIVIRAL THERAPY 8 (3), U50-U51",,0,2003
Preliminary characterization of a newly described protease substrate cleft mutation at position,"E Johnson, MA Winters, K Vyas, TC Merigan, RW Shafer","Antiviral Therapy 8 (3), U55-U55",,0,2003
About the translation of genotypic resistance interpretation in pehnotypic resistance-or: how many fold are intermediate?,"N Zeitler, B Schmidt, K Korn, W Keulen, C Boucher, N Beerenwinkel, ...","Hiv Medicine 4 (2), 179-180",,0,2003
A statistical model that identifies protease inhibitor treatment associated mutations in therapy-naïve patients infected with HIV,"D van de Vijver, R Schuurman, C Nielsen, M Salminen, J Albert, ...",Hiv Medicine 4 (2),,0,2003
Spectrum of HIV-1 reverse transcriptase mutations selected by nucleoside reverse transcriptase inhibitor treatment is greater than previously reported,"MJ Gonzales, T Wu, J Taylor, I Belitskaya, R Kantor, D Israelski, S Chou, ...","ANTIVIRAL THERAPY 7, S38-S38",,0,2002
Failure to detect HIV-1 re-infection based on serial protease and reverse transcriptase sequences during 1239 patient-years of observation,"SY Rhee, MJ Gonzales, E Delwart, RW Shafer","ANTIVIRAL THERAPY 7, S195-S195",,0,2002
PMCID: PMC478552.,"AR Zolopa, WJ Fessel, RW Shafer","Infect Dis 184 (8), 998-1006",,0,2001
The evolution of HIV-1 resistance mutations in two french couples,"S Palmer, V Hellmann, R Shafer, L Pallansch, TC Merigan, RW Buckheit, ...","ANTIVIRAL RESEARCH 46 (1), A49-A49",,0,2000
DOSSIER: AIDS INTENSIVE VIROSTATIC THERAPY-Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1,"RW Shafer, DA Vuitton","Biomedicine and Pharmacotherapy 53 (2), 73-86",,0,1999
BASIC SCIENCE-Sequence Notes-Sequence and Drug Susceptibility of Subtype C Protease from Human Immunodeficiency Virus Type 1 Seroconverters in Zimbabwe,"RW Shafer, TK Chuang, P Hsu, CB White, DA Katzenstein","AIDS Research and Human Retroviruses 15 (1), 65-70",,0,1999
RECOMBINATION AND EVOLUTION-Identification of Biased Amino Acid Substitution Patterns in Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Protease Inhibitors,"RW Shafer, P Hsu, AK Patick, C Craig, V Brendel","Journal of Virology 73 (7), 6197-6202",,0,1999
Identification of Biased Amino Acid,"V Brendel, RW Shafer, P Hsu, AK Patick, C Craig","J. Virol 73 (7), 6197",,0,1999
Postnatal transmission of AIDS-associated retrovirus from mother to infant.,"YM Mobarak, JC Adkins, DH Peters, D Faulds, GM Aldrovandi, C Chu, ...","Trends in Applied Sciences Research 6 (3), 1054-1080",,0,1997
A Correspondence,R Blaser,"The Capilano Review 2 (17-18), 97-109",,0,1996
"THE ASSOCIATION BETWEEN HIV PHENOTYPE, VIRUS BURDEN, CODON-215 MUTATION AND CD4 CELL DECLINE-REPLY","MJ Kozal, RW SHAFER, MA Winters, DA Katzenstein, J HALPERN, ...",JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 9 (1 …,,0,1995
Clarification of a Method to Reverse Transcribe Human Immunodeficiency Virus RNA,"MJ Kozal, RW Shafer, MA Winters, DA Katzenstein, TC Merigan","Journal of Infectious Diseases 171 (4), 1072-1072",,0,1995
PREDICTORS OF SURVIVAL IN HIV-SEROPOSITIVE (HIV+) TUBERCULOSIS (TB) PATIENTS (PTS) WITHOUT OTHER AIDS-DEFINING ILLNESSES,"RW SHAFER, C LARKIN, AB BLOCH, G DIFERDINANDO, ...","AMERICAN REVIEW OF RESPIRATORY DISEASE 147 (4), A490-A490",,0,1993
ANATOMIC AND ELECTRO-MYOGRAPHIC STUDY OF THE ANCONEUS MUSCLE,"J LECLAIRE, S RHEE, R SHAFER","ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION 60 (11), 526-526",,0,1979
Prevalence of drug-resistant minority variants in untreated HIV-1-infected individuals with and without transmitted drug resistance by Sanger sequencing,"DS Clutter, S Zhou, V Varghese, SY Rhee, BA Pinsky, WJ Fessel, ...",The Journal of Infectious Diseases,,0,0
Increasing and Unusual Genetic Diversity of HIV-1 in the UK,"R Gifford, T de Oliveira, A Rambaut, RE Myers, CV Gale, D Dunn, ...",,,0,0
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing Running Title: HIV-1 Drug Resistance Mutations,"SY Rhee, MR Jordan, E Raizes, A Chua, N Parkin, R Kantor, GU Van Zyl, ...",,,0,0
